Search

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

My name is Mark Baxter and from an early age I was diagnosed with a deteriorating retinal eye condition called retinitis pigmentosa or RP for short, which will slowly lead to blindness.

• Case study - community
• Written

Organising your own fundraising is great fun and a brilliant way to involve your friends, family and local community.

In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.

• News

In spring 2021, the US company jCyte announced detailed results from their successful phase 2b clinical trial of jCell, a stem cell-based treatment for RP.

• News
• Retinitis pigmentosa

The following projects were being funded by Retina UK and have recently come to an end.

Our community is informed and knowledgeable about current research projects into the cause(s) of and treatments for these conditions.

Growth factors are substances that promote the health and function of cells and tissues in the body.

Several groups around the world are investigating the use of retinal transplantation in the treatment of inherited retinal diseases.

Dr Rachel Taylor is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team at the University of Manchester.

• Case study - research
• Written